Shanghai HEP Pharma Signs Agreement with OmniComm Systems

Apr 10, 2018
By Applied Clinical Trials Editors

Shanghai HEP Pharma Co. has signed a new agreement with OmniComm Systems, Inc which will officially name them as TrialMaster's first customer in China. Under this agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC to conduct a hepatitis B study.

Read the full release here.

native1_300x100
lorem ipsum